The recall includes both losartan potassium tablets and losartan potassium hydrochlorothiazide tablets.
The recall is due to the presence of N-Nitroso N-Methyl 4-aminobutyric acid, a potential human carcinogen. Torrent already recalled three lots of losartan on March 15 and 114 lots of losartan on March 1.
Torrent’s recall is the latest in a string of voluntary recalls by distributors and drugmakers related to a class of drugs known as angiotensin II receptor blockers, used to control blood pressure. The recalls are related to the detection of various cancer-causing impurities.
Read the full recall notice here.
More articles on pharmacy:
PBM hearing should prompt bill to ban ‘secrecy’ in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
